Symbiotec Pharmalab Limited IPO

Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. The Company holds a global leadership position in corticosteroid and steroidal hormone active pharmaceutical ingredients (APIs) in volume terms, with significant market share in these segments (Source: F&S Report). Leveraging its strong R&D and manufacturing expertise, it also operates as a contract development and manufacturing organization (CDMO) for specialty pharmaceutical and nutraceutical companies. Through its integrated capabilities, Symbiotec Pharmalab serves global markets with high-quality, specialized pharmaceutical solutions.